Global Advanced Therapy Medicinal Products Market Analysis By Therapy Type (Cell Therapy, Gene Therapy, Tissue-Engineered Products, Combination/Joined ATMPs (e.g., cell + gene + scaffold), Others), By Product Type (Somatic Cell Therapy Products, Tissue-Engineered Medicinal Products, Gene Therapy Medicinal Products, Combined ATMPs / Multi-Modal Products, Others), By Application (Oncology, Genetic Disorders (e.g., inherited metabolic, haematologic), Neurology, Cardiovascular Diseases, Musculoskeletal / Orthopaedic (e.g., tissue repair), Ophthalmology, Dermatology, Others), By End-User (Hospitals and Clinics, Contract Development & Manufacturing Organizations (CDMOs), Biotechnology & Biopharma Companies, Research & Academic Institutes, Others) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034
- Published date: Nov 2025
- Report ID: 166507
- Number of Pages: 291
- Format:
-
keyboard_arrow_up
-
-
- Novartis AG Company Profile
- Gilead Sciences Inc. (via its subsidiary Kite Pharma Inc.)
- CRISPR Therapeutics AG
- Oxford Biomedica plc
- AGC Biologics Inc.
- Samsung Biologics Co. Ltd.
- FUJIFILM Diosynth Biotechnologies
- Lonza Group AG Company Profile
- Celltrion Inc.
- Thermo Fisher Scientific Company Profile
- Yposkesi (Erytech Pharma SA)
- Centre for Breakthrough Medicines LLC
- SCTbio a.s.
- Catalent Inc.
- Other key players
Our Clients
✖
Request a Sample Report
We'll get back to you as quickly as possible